Arcturus Therapeutics Holdings Inc (ARCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has a cash flow conversion efficiency ratio of -0.116x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.91 Million) by net assets ($171.81 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Arcturus Therapeutics Holdings Inc for the company's overall valuation and market capitalisation.
Arcturus Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcturus Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their cash flow conversion efficiency. Explore ARCT cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ABG Sundal Collier Holding ASA
OL:ABG
|
0.051x |
|
Zhuhai Kles Technology Co. Ltd. A
SHE:301314
|
N/A |
|
Lanpec Technologies Ltd
SHG:601798
|
0.028x |
|
Sunfly Intelligent Technology Co Ltd
SHE:300423
|
-0.016x |
|
Bonree Data Technology Co Ltd
SHG:688229
|
-0.049x |
|
Shanghai Laimu Electronics Co Ltd
SHG:603633
|
-0.006x |
|
Ambac Financial Group Inc
NYSE:AMBC
|
-0.036x |
|
Shoe Carnival Inc
NASDAQ:SCVL
|
0.034x |
Annual Cash Flow Conversion Efficiency for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Arcturus Therapeutics Holdings Inc from 2011 to 2025. View Arcturus Therapeutics Holdings Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $213.99 Million | $-74.27 Million | -0.347x | -39.99% |
| 2024-12-31 | $240.98 Million | $-59.75 Million | -0.248x | -281.53% |
| 2023-12-31 | $278.51 Million | $-18.10 Million | -0.065x | -154.91% |
| 2022-12-31 | $270.31 Million | $31.99 Million | 0.118x | +120.00% |
| 2021-12-31 | $228.21 Million | $-135.04 Million | -0.592x | -447.49% |
| 2020-12-31 | $396.55 Million | $-42.86 Million | -0.108x | +56.75% |
| 2019-12-31 | $25.79 Million | $-6.45 Million | -0.250x | +83.58% |
| 2018-12-31 | $13.64 Million | $-20.76 Million | -1.522x | -11079.72% |
| 2017-12-31 | $33.79 Million | $-460.00K | -0.014x | +96.66% |
| 2016-12-31 | $47.23 Million | $-19.24 Million | -0.407x | -55.64% |
| 2015-12-31 | $69.33 Million | $-18.15 Million | -0.262x | +81.57% |
| 2014-12-31 | $19.94 Million | $-28.33 Million | -1.420x | -840.49% |
| 2013-12-31 | $48.69 Million | $-7.35 Million | -0.151x | -105.40% |
| 2012-12-31 | $-567.00K | $-1.58 Million | 2.795x | +216.62% |
| 2011-12-31 | $985.00K | $-2.36 Million | -2.397x | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more